• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Left ventricular hypertrophy is a leading risk factor for cardiovascular morbidity and mortality.
Although reverse ventricular remodelling was long thought to be irreversible, evidence from …

Pathogenic variants in genes that cause dilated cardiomyopathy (DCM) and arrhythmogenic
cardiomyopathy (ACM) convey high risks for the development of heart failure through …

Background Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to
5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and …

Background Although genotyping allows family screening and influences risk-stratification in
patients with nonischemic dilated cardiomyopathy (DCM) or isolated left ventricular systolic …

Background Dilated cardiomyopathy (DCM) is a final common manifestation of
heterogenous etiologies. Adverse outcomes highlight the need for disease stratification …

BACKGROUND: LMNA (lamin A/C)-related dilated cardiomyopathy is a rare genetic cause
of heart failure. In a phase 2 trial and long-term extension, the selective p38α MAPK …

The authors present a clinical report focused on the overlap between myocarditis and
genetic cardiomyopathies of the dilated and arrhythmogenic spectrum. Our cohort was …

With the development and advancement of next-generation sequencing (NGS), genetic
analysis is becoming more accessible. High-throughput genetic studies using NGS have …

Dilated cardiomyopathy (DCM) is a complex disease with multiple causes and various
pathogenic mechanisms. Despite improvements in the prognosis of patients with DCM in the …